Brief but chronic increase in allopregnanolone cause accelerated ad pathology differently in two mouse models

Current Alzheimer Research

Volumn 10, Issue 1, 2013, Pages 38-47

  Bengtsson, Sara K ^a   Johansson, Maja ^a   Bäckström, Torbjörn ^a   Nitsch, Roger M ^b   Wang, Mingde ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Allopregnanolone; Alzheimer's disease; Cognition; Physiological stress; Transgenic

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID RECEPTOR; ALCOHOL; AMYLOID PRECURSOR PROTEIN; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; HYDROCORTISONE DERIVATIVE; MEDROXYPROGESTERONE ACETATE; AMYLOID BETA PROTEIN; ANESTHETIC AGENT; ELTANOLONE; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BRAIN REGION; CHRONIC STRESS; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENOTYPE; LEARNING DISORDER; LONG TERM CARE; LONG TERM EXPOSURE; MALE; MAZE TEST; MEMORY; MEMORY DISORDER; MODEL; MORRIS WATER MAZE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; SWIMMING; TRAINING; TRANSGENIC MOUSE; TREATMENT OUTCOME; WILD TYPE; ANIMAL; C57BL MOUSE; DBA MOUSE; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECT; GENETICS; HIPPOCAMPUS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; SEX DIFFERENCE; TIME;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANESTHETICS; ANIMALS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; MUTATION; PREGNANOLONE; PRESENILIN-1; SEX FACTORS; TIME FACTORS;

EID: 84882329313     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720513804871363     Document Type: Article

References (56)

1. Davies P, Anderton B, Kirsch J, Konnerth A, Nitsch R, Sheetz M. First one in, last one out: the role of GABAergic transmission in generation and degeneration. Prog Neurobiol 55(6): 651-8 (1998).
2. Garcia-Alloza M, Tsang SW, Gil-Bea FJ, Francis PT, Lai MK, Marcos B, et al. Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiol Aging 27(8): 1110-7 (2006).
3. Mellon SH, Gong W, Schonemann MD. Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease. Brain Res Rev 57(2): 410-20 (2008).
4. Purdy RH, Morrow AL, Moore PH, Jr., Paul SM. Stress-induced elevations of g-aminobutyric acid type A receptor- active steroids in the rat brain. Proc Natl Acad Sci 88(10): 4553-7 (1991).
5. Stromberg J, Haage D, Taube M, Backstrom T, Lundgren P. Neu-rosteroid modulation of allopregnanolone and GABA effect on the GABA-A receptor. Neuroscience 143(1): 73-81 (2006).
6. Majewska MD, Harrison NL, Schwartz R, Baker J, Paul SM. Ster-oid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232: 1004-7 (1986).
7. Bernardi F, Lanzone A, Cento R, Spada R, Pezzani I, Genazzani A, et al. Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia. Eur J Endocrinol 142(5): 466-71 (2000).
8. Smith C, Wekstein D, Markesbery W, Frye C. 3a,5a-THP: a poten-tial plasma neurosteroid biomarker in Alzheimer's disease and perhaps non-Alzheimer's dementia. Psychopharmacology 186(3): 481-5 (2006).
9. Rissman RA, Mishizen-Eberz AJ, Carter TL, Wolfe BB, De Blas AL, Miralles CP, et al. Biochemical analysis of GABAA receptor subunits (alpha) 1, (alpha)5, (beta)1, (beta)2 in the hippocampus of patients with Alzheimer's disease neuropathology. Neuroscience 120(3): 695-704 (2003).
10. Rissman RA, De Blas AL, Armstrong DM. GABAA receptors in aging and Alzheimer's disease. J Neurochem 103(4): 1285-92 (2007).
11. Belelli D, Casula A, Ling A, Lambert JJ. The influence of subunit composition on the interaction of neurosteroids with GABAA receptors. Neuropharmacology 43(4): 651-61 (2002).
12. Serra M, Pisu MG, Littera M, Papi G, Sanna E, Tuveri F, et al. Social isolation-induced decreases in both the abundance of neuro-active steroids and GABAA receptor function in rat brain. J Neuro-chem 75(2): 732-40 (2000).
13. Droogleever Fortuyn HA, van Broekhoven F, Span PN, Bäckström T, Zitman FG, Verkes RJ. Effects of PhD examination stress on al-lopregnanolone and cortisol plasma levels and peripheral benzodiazepine receptor density. Psychoneuroendocrinology 29(10): 1341-4 (2004).
14. Vallée M, Rivera JD, Koob GF, Purdy RH, Fitzgerald RL. Quantification of neurosteroids in rat plasma and brain following swim stress and allopregnanolone administration using negative chemical ionization gas chromatography/mass spectrometry. Anal Biochem 287(1): 153-66 (2000).
15. Lupien SJ, Fiocco A, Wan N, Maheu F, Lord C, Schramek T, et al. Stress hormones and human memory function across the lifespan. Psychoneuroendocrinology 30(3): 225-42 (2005).
16. Sandström A, Rhodin IN, Lundberg M, Olsson T, Nyberg L. Impaired cognitive performance in patients with chronic burnout syndrome. Biol Psychol 69(3): 271-9 (2005).
17. Johansson L, Guo X, Waern M, Ostling S, Gustafson D, Bengtsson C, et al. Midlife psychological stress and risk of dementia: a 35-year longitudinal population study. Brain 133(8): 2217-24 (2010).
18. Vitaliano PP, Murphy M, Young HM, Echeverria D, Borson S. Does caring for a spouse with dementia promote cognitive decline? A hypothesis and proposed mechanisms. J Am Geriatr Soc 59(5): 900-8 (2011).
19. Yaffe K, Vittinghoff E, Lindquist K, Barnes D, Covinsky KE, Neykan T, et al. Post-traumatic stress disorder and risk of dementia among U.S. veterans. Arch Gen Psychiatry 67(6): 608-13 (2010).
20. Stromberg J, Backstrom T, Lundgren P. Rapid non-genomic effect of glucocorticoid metabolites and neurosteroids on the y-aminobutyric acid-A receptor. Eur J Neurosci 21: 2083-8 (2005).
21. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 19(3): 437-54 (2004).
22. Saunders PA, Copeland JR, Dewey ME, Davidson IA, McWilliam C, Sharma V, et al. Heavy drinking as a risk factor for depression and dementia in elderly men. Findings from the Liverpool longitudinal community study. Br J Psychiatry 159: 213-6 (1991).
23. Mohammed AK, Wahlstrom G, Tiger G, Björklund PE, Stenström A, Magnusson O, et al. Impaired performance of rats in the Morris swim-maize test late in abstinence following long-term sodium barbital treatment. Drug Alcohol Depend 20(3): 203-12 (1987).
24. Meyerson B. Relationship between the anesthetic and gestagenic action and estrous behavior-inducing activity of different progestins. Endocrinology 81(2): 369-74 (1967).
25. Norberg L, Wahlstrom G, Backstrom T. The anaesthetic potency of 3 alpha-hydroxy-5 alpha-pregnan-20-one and 3 alpha-hydroxy-5 beta-pregnan-20-one determined with an intravenous EEG-threshold method in male rats. Pharmacol Toxicol 61(1): 42-7 (1987).
26. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289(20): 2651-62 (2003).
27. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. JAMA 291(24): 2947-58 (2004).
28. Coker Coker LH, Hogan PE, Bryan NR, Kuller LH, Margolis KL, Bettermann K, et al. Postmenopausal hormone therapy and subclinical cerebrovascular disease. Neurology 72(2): 125-34 (2009).
29. Coker LH, Espeland MA, Rapp SR, Legault C, Resnick SM, Hogan P, et al. Postmenopausal hormone therapy and cognitive outcomes: The Women's Health Initiative Memory Study (WHIMS). J Steroid Biochem Mol Biol 118(4-5): 304-10 (2010).
30. Honjo H, Iwasa K, Kawata M, Fushiki S, Hosoda T, Tatsumi H, et al. Progestins and estrogens and Alzheimer's disease. J Steroid Biochem Mol Biol 93(2-5): 305-8 (2005).
31. Braden B, Garcia A, Mennenga S, Prokai L, Villa S, Acosta J, et al. Cognitive-impairing effects of medroxyprogesterone acetate in the rat: independent and interactive effects across time. Psychopharma-cology 218(2): 405-18 (2011).
32. Braden B, Talboom JS, Crain ID, Simard AR, Lukas RJ, Prokai L, et al. Medroxyprogesterone acetate impairs memory and alters the GABAergic system in aged surgically menopausal rats. Neurobiol Learn Mem 93(3): 444-53 (2010).
33. Bengtsson SK, Johansson M, Bäckström T, Wang M. Chronic Allopregnanolone Treatment Accelerates Alzheimer's Disease Development in ApPPSwePSEN1AE9 Mice. J Alzheimer Dis 31(1): 71-84 (2012).
34. Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular Ab and cognitive deficits precede b-amyloid deposition in transgenic arcAb mice. Neurobiol Aging 28(9): 1297-306 (2007).
35. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3(1): 67-72 (1997).
36. Mehta ND, Refolo LM, Eckman C, Sanders S, Yager D, Perez-Tur J, et al. Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol 43(2): 256-8 (1998).
37. Ding Y, Qiao A, Wang Z, Goodwin JS, Lee E-S, Block ML, et al. Retinoic Acid Attenuates b-Amyloid Deposition and Rescues Memory Deficits in an Alzheimer's Disease Transgenic Mouse Model. J Neurosci 28(45): 11622-34 (2008).
38. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 55(6): 801-14 (2004).
39. Lalonde R, Kim HD, Maxwell JA, Fukuchi K. Exploratory activity and spatial learning in 12-month-old APP695SWE/co + PS1/DE9 mice with amyloid plaques. Neurosci Lett 390(2): 87-92 (2005).
40. Cao D, Lu H, Lewis TL, Li L. Intake of Sucrose-sweetened Water Induces Insulin Resistance and Exacerbates Memory Deficits and Amyloidosis in a Transgenic Mouse Model of Alzheimer Disease. J Biol Chem 282(50): 36275-82 (2007).
41. Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT, et al. Effects of synaptic modulation on b-amyloid, synapto-physin, and memory performance in Alzheimer's disease transgenic mice. J Neurosci 30(43): 14299-304 (2010).
42. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 5(11): 956-70 (2006).
43. Lord A, Englund H, Söderberg L, Tucker S, Clausen F, Hillered L, et al. Amyloid-b; protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J 276(4): 995-1006 (2009).
44. Li S, Wang C, Wang W, Dong H, Hou P, Tang Y. Chronic mild stress impairs cognition in mice: From brain homeostasis to behavior. Life Sci 82(17-18): 934-42 (2008).
45. Alkadhi KA, Srivareerat M, Tran TT. Intensification of long-term memory deficit by chronic stress and prevention by nicotine in a rat model of Alzheimer's disease. Mol Cell Neurosci 45(3): 289-96 (2010).
46. Jeong YH, Park CH, Yoo J, Shin KY, Ahn S-M, Kim H-S, et al. Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J 20(6): 729-40 (2006).
47. Melnikova T, Savonenko A, Wang Q, Liang X, Hand T, Wu L, et al. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 141(3): 1149-62 (2006).
48. Lue L-F, Kuo Y-M, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloidb peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155(3): 853-62 (1999).
49. Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Ta-tsuno G, et al. High-Level Neuronal Expression of Abeta 1-42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation. J Neurosci 20(11): 4050-8 (2000).
50. McLean CA, Cherny RA, Fraser PW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46(6): 860-6 (1999).
51. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Green-gard P, et al. Correlation between elevated levels of amyloid b-peptide in the brain and cognitive decline. JAMA 283(12): 1571-7 (2000).
52. Christensen D, Kraus S, Flohr A, Cotel M-C, Wirths O, Bayer T. Transient intraneuronal Ap rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathologica 116(6): 647-55 (2008).
53. Gouras G, Tampellini D, Takahashi R, Capetillo-Zarate E. Intraneuronal p-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathologica 119(5): 523-41 (2010).
54. Liu J, Fukunaga K, Yamamoto H, Nishi K, Miyamoto E. Differential Roles of Ca2+/Calmodulin-Dependent Protein Kinase II and Mitogen-Activated Protein Kinase Activation in Hippocampal Long-Term Potentiation. J Neurosci 19(19): 8292-9 (1999).
55. Selkoe DJ. Alzheimer's Disease Is a Synaptic Failure. Science 298(5594): 789-91 (2002).
56. Bernardi F, Pluchino N, Pieri M, Begliuomini S, Lenzi E, Puccetti S, et al. Progesterone and medroxyprogesterone acetate effects on central and peripheral allopregnanolone and beta-endorphin levels. Neuroendocrinology 83(5-6):348-59 (2006).